International Business Machines Corporation

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Buy, Hold, or Sell: IBM Just Shed 16% Is It a Clear Buy at $268? - 24/7 Wall St.

📉 IBM stock has pulled back 16% from its January peak near $314.84, currently trading at $268.71 with a forward P/E of 22.

💰 Q1 2026 results were clean, featuring revenue of $15.92 billion and record free cash flow of $2.22 billion, a 13% year-over-year increase.

🚀 Software segment grew 11.3% while Infrastructure climbed 15.3%, driven by a 51% surge in IBM Z mainframe revenue.

🤖 The generative AI book of business cleared $12.5 billion inception-to-date, with Consulting GenAI exceeding $4 billion ARR.

⚠️ Consulting segment growth lagged at just 1% constant currency, raising concerns about enterprise discretionary spend.

📊 Analyst consensus target is $290.89, implying modest upside despite the stock being down 8.09% year-to-date against a rising S&P 500.

💸 The company carries $61.3 billion in total debt, making it sensitive to Federal Reserve quantitative tightening and rate shocks.

📈 Operating income jumped 20.62% year-over-year, reflecting strong operational execution across core segments.

🛡️ IBM has increased its dividend for the 31st consecutive year, providing a 2.44% yield to shareholders.

🔍 Key invalidation risks include Software growth dropping below 10% or the AI book stalling for two consecutive quarters.

Bullish Signals
  • IBM posted its highest first-quarter free cash flow in a decade at $2.22 billion, representing a 13% year-over-year increase.
  • Software revenue grew 11.3% and Infrastructure climbed 15.3%, with IBM Z mainframe revenue surging 51%.
  • Operating income jumped 20.62% year-over-year, demonstrating strong profitability despite market headwinds.
  • The generative AI book of business reached $12.5 billion by the end of 2025, providing a tangible revenue pipeline.
  • Consulting GenAI alone has eclipsed $4 billion in annual recurring revenue, indicating successful AI monetization.
  • IBM has increased its dividend for 31 consecutive years, offering a stable 2.44% yield to investors.
  • The stock trades at a forward P/E of 22 and trailing P/E of 24, which the article deems unusually reasonable compared to fundamentals.
  • Recent insider activity includes director fee-share grants, suggesting management confidence in the company's structure.
Risk Factors
  • Consulting segment grew only 1% on a constant currency basis, signaling potential weakness in enterprise discretionary spending.
  • The stock is down 8.09% year-to-date while the S&P 500 gained 10.69%, indicating relative underperformance.
  • Two Strong Sell ratings sit alongside seven Hold ratings among 22 covering analysts, reflecting mixed sentiment.
  • IBM trades at 7.76x book value with $61.3 billion in total debt, creating vulnerability to sustained rate shocks and multiple compression.
  • The 200-day moving average of $273.07 sits just above the current price, acting as overhead resistance for near-term upside.
  • Recent insider activity skews toward director fee-share grants rather than discretionary open-market buying by executives.
  • If the AI book stops compounding or Software growth slips below 10%, the multiple could face further downside pressure.
Full Analysis
International Business Machines (IBM) stock is trading at $268.71, having pulled back significantly from its January peak near $314.84. The article argues the stock is attractively valued with a forward P/E of 22 and a trailing P/E of 24, while offering a 2.44% dividend yield supported by 31 consecutive years of increases. This valuation gap between price and fundamentals is attributed to broader market compression due to Federal Reserve quantitative tightening rather than deteriorating company-specific execution. IBM reported its highest first-quarter free cash flow in a decade, with revenue of $15.92 billion beating estimates by 1.70% and EPS of $1.91 exceeding expectations by 5.45%. Free cash flow rose 13% year-over-year to $2.22 billion, driven by double-digit growth in the Software segment (11.3%) and Infrastructure (15.3%), which saw a 51% surge in IBM Z mainframe revenue. Operating income jumped 20.62% year-over-year, highlighting strong operational performance despite the stock's underperformance relative to the S&P 500. The company has built a substantial generative AI pipeline, with the total GenAI book of business reaching $12.5 billion by the end of 2025 and Consulting GenAI alone surpassing $4 billion in annual recurring revenue. However, the Consulting segment grew only 1% on a constant currency basis, signaling potential softness in enterprise discretionary spending. Analyst consensus targets suggest modest upside to $290.89, with the stock down 8.09% year-to-date as investors await confirmation of continued growth in Q2. Key risks include the potential for sustained rate shocks affecting IBM's multiple and financing costs given its $61.3 billion total debt load following acquisitions like Confluent. The thesis could be invalidated if Software growth slips below 10%, the AI book stalls for two consecutive quarters, or demand for the Z17 mainframe fades after the current refresh cycle. Investors are advised to watch Q2 results for Consulting acceleration and any potential guidance raises from management.